KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Depreciation & Amortization - Total: 2011-2023

Historic Depreciation & Amortization - Total for TherapeuticsMD (TXMD) over the last 3 years, with Dec 2023 value amounting to -$185,000.

  • TherapeuticsMD's Depreciation & Amortization - Total rose 34.86% to -$185,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $100,000, marking a year-over-year decrease of 83.33%. This contributed to the annual value of $100,000 for FY2023, which is 83.33% down from last year.
  • TherapeuticsMD's Depreciation & Amortization - Total amounted to -$185,000 in Q4 2023, which was down 242.31% from $130,000 recorded in Q3 2023.
  • TherapeuticsMD's Depreciation & Amortization - Total's 5-year high stood at $329,000 during Q1 2022, with a 5-year trough of -$284,000 in Q4 2022.
  • In the last 2 years, TherapeuticsMD's Depreciation & Amortization - Total had a median value of $129,000 in 2023 and averaged $87,500.
  • Its Depreciation & Amortization - Total has fluctuated over the past 5 years, first skyrocketed by 73.05% in 2019, then tumbled by 91.79% in 2023.
  • TherapeuticsMD's Depreciation & Amortization - Total (Quarterly) stood at $66,493 in 2019, then reached -$284,000 in 2022, then surged by 34.86% to -$185,000 in 2023.
  • Its Depreciation & Amortization - Total was -$185,000 in Q4 2023, compared to $130,000 in Q3 2023 and $128,000 in Q2 2023.